Medical Treatments: Innovation

(asked on 12th October 2017) - View Source

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health, what assessment he has made of the compatibility of the system-wide cap of £20 million for NICE approved medicines proposed by NHS England with the aims and objectives of the Accelerated Access Review; and if he will make a statement.


Answered by
Steve Brine Portrait
Steve Brine
This question was answered on 19th October 2017

The Government considers that the introduction of the budget impact test in April this year for technologies with an annual budget impact greater than £20 million per year is fully in line with the aims and objectives of the Accelerated Access Review.

Under the budget impact test, £20 million does not represent a cap on what the National Health Service will spend on any individual drug in a given year. The test is simply intended to provide an opportunity for NHS England to enter into commercial negotiations with companies to bring down the price of very high cost medicines. The opportunity for companies to negotiate with NHS England will enable new types of commercial arrangement, which means that ‘win-win’ scenarios are possible for the NHS and industry, a key aim of the Accelerated Access Review.

Reticulating Splines